Unim Brigid, Saulle Rosella, Boccalini Sara, Taddei Cristina, Ceccherini Vega, Boccia Antonio, Bonanni Paolo, La Torre Giuseppe
Department of Public Health and Infectious Diseases; Sapienza University of Rome; Rome, Italy.
Hum Vaccin Immunother. 2013 Sep;9(9):1932-42. doi: 10.4161/hv.25228. Epub 2013 Jul 3.
The aim of the present study is to review the economic burden of varicella disease and the benefit of universal varicella vaccination in different settings pending its implementation in all Italian regions.
Research was conducted using PubMed, Scopus and ISI databases. Score quality and data extraction were performed for all included studies.
Twenty-three articles met the criteria: 15 cost-effectiveness, 8 cost-benefit and one cost-utility analysis. Varicella vaccination could save the society from €637,762 (infant strategy) to 53 million annually (combined infant and adolescent strategy). The median and the mean quality scores resulted in 91.8% and 85.4% respectively; 11 studies were considered of high quality and 12 of low quality.
The studies are favorable to the introduction of universal varicella vaccination in Italy, being cost saving and having a positive impact on morbidity. The quality score of the studies varied greatly: recent analyses were of comparable quality to older studies.
本研究旨在回顾水痘疾病的经济负担以及在意大利所有地区实施全民水痘疫苗接种之前，在不同环境下进行全民水痘疫苗接种的益处。
使用PubMed、Scopus和ISI数据库进行研究。对所有纳入研究进行评分质量评估和数据提取。
23篇文章符合标准：15篇成本效益分析、8篇成本效益分析和1篇成本效用分析。水痘疫苗接种每年可为社会节省637,762欧元（婴儿策略）至5300万欧元（婴儿和青少年联合策略）。中位数和平均质量得分分别为91.8%和85.4%；11项研究被认为质量高，12项质量低。
这些研究支持在意大利引入全民水痘疫苗接种，因为这既能节省成本，又能对发病率产生积极影响。研究的质量得分差异很大：近期分析的质量与早期研究相当。
